Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Update: Japan Approves Lagevrio, Korea Clears Paxlovid

Plus, Boosters In Japan, Further Vaccine Progress In Korea

Executive Summary

Oral antivirals make progress in Asia as Japan issues emergency approval to Merck's Lagevrio in a matter of weeks and South Korea clears Pfizer's contender Paxlovid. Vaccines also move forward in both countries with deals for boosters, new supply agreements and the advancement of home-grown candidates.  

You may also be interested in...



Shionogi Files Oral COVID Antiviral In Japan, Vaccine Shows Phase III Promise

Shionogi announces plans to file for rapid Japan approval of S-217622, its once-daily oral therapeutic drug for COVID-19, while interim Phase III results show good efficacy for S-268019, its recombinant protein vaccine for SARS-CoV-2. Both are expected to be the first Japan-made solutions for the disease and could make a significant impact in the market.

Coronavirus Update: Japan Paxlovid Approval, US Lifts Covaxin IND Hold

Japan has added to its growing arsenal of COVID-19 treatments with the approval of the oral antiviral Paxlovid, while the US FDA has lifted a clinical hold on Bharat's vaccine, which has shown potential against Omicron. Also, Biological E's vaccine is approved for use in adolescents in India

Coronavirus Update: Generics And Hurdles For Molnupiravir, More Japan Approvals

More generic deals but also US approval hurdles for Merck's oral antiviral, while Japan approves more options and Valneva's vaccine candidate shows promise against Omicron. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145632

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel